You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoproliferative Disorders

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)

Not yet recruiting
  • Lymphoma, Mantle-Cell
  • +7 more
  • (no location specified)
Jun 21, 2022

Early Detection of Epstein-Barr Virus Related Disease.

Active, not recruiting
  • Post-transplant Lymphoproliferative Disorder
  • +8 more
    • Aarhus, Central Region Of Denmark, Denmark
      Aarhus University Hospital
    Dec 12, 2022

    Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease Trial in Saint Louis (Transplant

    Recruiting
    • Immune Deficiency Disorders
    • +13 more
    • Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
    • Saint Louis, Missouri
      Washington University
    Apr 25, 2022

    Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder Trial in Boston (Pirtobrutinib, Venetoclax, Allopurinol)

    Not yet recruiting
    • Waldenstrom Macroglobulinemia
    • B-Cell Lymphoproliferative Disorder
    • Boston, Massachusetts
    • +2 more
    Feb 18, 2023

    Clinical, Laboratory and Epidemiologic Characterization of

    Recruiting
    • Waldenstrom Macroglobulinemia
    • +4 more
      • Bethesda, Maryland
      • +1 more
      Jan 25, 2023

      Family Study of Lymphoproliferative Disorders

      Recruiting
      • Lymphoma, Non-Hodgkin
      • +4 more
        • Rochester, Minnesota
          Mayo Clinic
        Aug 30, 2021

        Ascertainment of Families for Genetic Studies of Familial

        Recruiting
        • Lymphoma
        • +4 more
          • Basking Ridge, New Jersey
          • +5 more
          Oct 7, 2021

          Post-transplant Lymphoproliferative Disease, Transplant-Related Hematologic Malignancy Trial in London (Autologous EBV-CTL

          Active, not recruiting
          • Post-transplant Lymphoproliferative Disease
          • Transplant-Related Hematologic Malignancy
          • Autologous EBV-CTL transduced with vector SFG-CNA12
          • +2 more
          • London, United Kingdom
          • +1 more
          Jan 19, 2022

          Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma Trial (tabelecleucel)

          Available
          • Epstein-Barr Virus (EBV) Infections
          • +11 more
          • tabelecleucel
          • (no location specified)
          Feb 15, 2022

          BD OneFlow CLPD Panel on BD FACSLyric System.

          Recruiting
          • Chronic Lymphoproliferative Diseases (CLPD)
          • BD OneFlow LST, and B-CLPD T1 to T4 Assays
          • Chapel Hill, North Carolina
          • +4 more
          Jan 19, 2023

          Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Trial

          Not yet recruiting
          • Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
          • Polymorphic Post-Transplant Lymphoproliferative Disorder
          • Biopsy
          • +5 more
          • New Brunswick, New Jersey
          • +2 more
          Mar 23, 2023

          Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease Trial in Houston (EBV-specific T cells: A, EBV-specific T

          Recruiting
          • Hodgkin's Disease
          • +3 more
          • EBV-specific T cells: A
          • EBV-specific T cells: B
          • Houston, Texas
          • +1 more
          Jun 28, 2022

          Lymphoproliferative Disorder, HHV-8, Malignancy Trial run by the National Cancer Institute (NCI) (Etoposide, Interferon-alpha,

          Active, not recruiting
          • Lymphoproliferative Disorder
          • +3 more
          • Bethesda, Maryland
            National Institutes of Health Clinical Center, 9000 Rockville Pi
          Aug 24, 2022

          Epstein-Barr Virus Infections Trial in Strasbourg (Rituximab, control group)

          Recruiting
          • Epstein-Barr Virus Infections
          • Strasbourg, France
            Les Hôpitaux Universitaires de Strasbourg
          Dec 7, 2021

          EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD) Trial in Switzerland (Donor-derived ex-vivo expanded EBV Tscm

          Not yet recruiting
          • EBV Lymphoma
          • Post-transplant Lymphoproliferative Disease (PTLD)
          • Donor-derived ex-vivo expanded EBV Tscm CTL
          • Basel, Switzerland
          • +7 more
          Jan 25, 2023

          Epstein-Barr Virus Infections, Post-Transplant Lymphoproliferative Disorder, Lymphoma Trial in Montreal (Group A, Group B)

          Recruiting
          • Epstein-Barr Virus Infections
          • +2 more
          • Group A
          • Group B
          • Montreal, Quebec, Canada
            Hôpital Maisonneuve-Rosemont
          Apr 5, 2022

          Expression of CD19 Complex in Lymphoproliferative Disorders

          Not yet recruiting
          • Lymphoproliferative Disorders
          • Flow cytometry
          • (no location specified)
          Feb 2, 2021

          Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus Trial in Houston (MABEL CTLs, Cyclophosphamide,

          Recruiting
          • Hodgkin Disease
          • +5 more
          • MABEL CTLs
          • +2 more
          • Houston, Texas
          • +1 more
          Jan 13, 2023

          Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Seattle

          Not yet recruiting
          • Post-Transplant Lymphoproliferative Disorder
          • +10 more
          • Loncastuximab Tesirine
          • Seattle, Washington
            Fred Hutch/University of Washington Cancer Consortium
          Jul 6, 2022

          EBV-Related Hodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Non-Hodgkin's Lymphoma Trial in Houston (Dose Level 1A:

          Not yet recruiting
          • EBV-Related Hodgkin Lymphoma
          • +2 more
          • Dose Level 1A: 2 x 10^7 cells/m2
          • +4 more
          • Houston, Texas
          • +1 more
          Feb 7, 2022

          Lymphoma, Lymphoma, Mantle-Cell, Tumors by Histologic Type Trial (IM19 CAR-T cells, Cyclophosphamide, Fludarabine)

          Not yet recruiting
          • Lymphoma
          • +4 more
          • IM19 CAR-T cells
          • +2 more
          • (no location specified)
          Nov 30, 2021

          Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 cells)

          Active, not recruiting
          • Hodgkin Disease
          • +8 more
          • ATLCAR.CD30 cells
          • Chapel Hill, North Carolina
          • +1 more
          Mar 2, 2022

          Brain and CNS Tumors, Chronic Myeloproliferative Disorders, Leukemia Trial in Detroit (3'-deoxy-3'-[18F]fluorothymidine)

          Recruiting
          • Brain and Central Nervous System Tumors
          • +8 more
          • 3'-deoxy-3'-[18F]fluorothymidine
          • Detroit, Michigan
            Barbara Ann Karmanos Cancer Institute
          Mar 30, 2022

          Multiple Myeloma, Tumor, Plasma Cell, Tumors by Histologic Type Trial in United States (CYNK-001)

          Active, not recruiting
          • Multiple Myeloma
          • +19 more
          • CYNK-001
          • Denver, Colorado
          • +8 more
          May 24, 2022

          Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Chronic Lymphocytic Leukemia Trial in Ann Arbor (Pacritinib)

          Terminated
          • Lymphoma, T-Cell, Cutaneous
          • +6 more
          • Ann Arbor, Michigan
            University of Michigan Rogel Cancer Center
          Jan 20, 2021